SOA201 is a EphA10-trispecific immune cell engager antibody, the second broad-spectrum trispecific antibody drug under the platform “Trispecific T cell engager antibody”.
SOA201 is and the world’s first trispecific antibody with EphA10 as the tumor target and activates both natural killer cells and T-cells. Its current development aims to treat cancers in women, such as breast cancer (including triple-negative breast cancer) and ovarian cancer.